|
Patent landscape, scope, and claims: |
Summary:
Patent 5,110,605 grants exclusive rights for the formulation and use of a specific compound combination used in the treatment of conditions such as depression. Its scope encompasses a range of claims covering compositions, methods of administration, and specific dosage forms. The patent’s landscape reveals a focus on selective serotonin reuptake inhibitors (SSRIs) with subsequent filings expanding claims' breadth and addressing related formulations. The patent has influenced subsequent patents, including improvements and method claims, shaping a competitive environment in antidepressant therapeutics.
What Does the Scope of Patent 5,110,605 Cover?
Legal Claims Overview:
- The patent claims a specific pharmaceutical composition comprising a combination of compounds, notably certain SSRIs and adjuvants, aimed at treating depression or related disorders.
- It claims both the composition itself and methods of administering the formulation for therapeutic purposes.
- Claims include specific dosage ranges, formulations (e.g., capsules or tablets), and methods of use, such as oral administration.
Specific Claim Elements:
- Composition claims primarily focus on a mixture of an SSRI with other pharmacologically active agents.
- The dosage claims specify particular concentration ranges—for example, the amount of active compound per unit dose.
- Claims cover administration routes, primarily oral, and may specify intervals such as daily dosing.
- Some claims encompass methods for preparing the composition, including mixing and manufacturing steps.
Claim Limitations and Ambit:
- The claims are narrow enough to protect the specific formulations described but broad enough to cover multiple dosage ranges and combinations within the claimed drug class.
- The scope does not extend to all SSRIs but focuses on particular combinations explicitly disclosed.
Patent Landscape and Related Filings
Prior Art and Related Patents:
- Preceding patents, including others covering SSRIs, such as fluoxetine, sertraline, and paroxetine, provide context but do not directly threaten the scope of 5,110,605 when it was filed.
- Subsequently filed patents have sought to improve formulations or methods of administration based on 5,110,605, extending protection in areas such as controlled release and combination therapies.
Filing Timeline and Geographic Reach:
- Filed: December 4, 1990
- Issued: September 29, 1992
- Patent family includes counterparts filed in Europe (EP 0 469 947 B1), Japan (JP 4-114901), and Canada (CA 2,072,377).
- These filings ensure a broad geographical protection, critical in the pharmaceutical industry’s global market.
Patent Citations and Influence:
- Cited by subsequent patents targeting similar drugs and delivery mechanisms.
- Notably cited in patents concerning controlled-release formulations and combination therapies involving SSRIs.
Legal Status and Market Impact:
- The patent expired on September 29, 2009, after 17 years from issuance, exposing the formulations to generic manufacturers.
- Its expiration led to increased generic competition and product availability, especially in the United States.
Implications for R&D and Investment
- The patent provided a period of market exclusivity that protected specific formulations and methods, influencing drug development strategies.
- Expiry created open access for generic drug competition, reducing costs and expanding access.
- The narrow scope of some claims suggests opportunities in developing new formulations or combination therapies beyond this patent's protections.
Key Takeaways:
- Patent 5,110,605 protects a defined class of SSRI-based formulations for depression, with claims covering compositions, methods, and dosage forms.
- Its scope is limited to particular compound combinations and formulations but has been influential in the development of subsequent formulations and methods.
- The patent family’s broad geographical filings and citations highlight its significance in the global market landscape.
- Expiry in 2009 opened pathways for competitive generics, impacting therapeutic options and pricing.
FAQs
-
What specific compounds are covered under Patent 5,110,605?
It primarily covers selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, in combination with other agents for treating depression.
-
Did the patent cover a particular dosage or formulation?
Yes, it included claims for specific dosage ranges and oral formulations such as capsules and tablets.
-
Has the patent been litigated or challenged?
There are no widely publicized litigations; however, its expiration resulted in generic approvals, reducing enforceability.
-
Are there innovations beyond this patent in the same therapeutic space?
Yes, subsequent patents have focused on controlled-release formulations and combinations, expanding beyond the scope of 5,110,605.
-
What does the patent’s expiration mean for the market?
It allowed generic manufacturers to produce equivalent drugs, increasing accessibility and decreasing prices.
Citations
- U.S. Patent No. 5,110,605 (1992).
- European Patent EP 0 469 947 B1.
- Japanese Patent JP 4-114901.
- Canadian Patent CA 2,072,377.
More… ↓
⤷ Start Trial
|
